Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: An individual patient data meta-analysis

Clinical Infectious Diseases

Volumn 59, Issue 10, 2014, Pages 1364-1374

  Bastos, Mayara L ^a,b   Hussain, Hamidah ^c   Weyer, Karin ^d   Garcia Garcia, Lourdes ^e   Leimane, Vaira ^f   Leung, Chi Chiu ^g   Narita, Masahiro ^h   Penã, Jose M ⁱ   Ponce De Leon, Alfredo ^j   Seung, Kwonjune J ^k   Shean, Karen ^l   Sifuentes Osornio, José ^j   Van Der Walt, Martie ^m   Van Der Werf, Tjip S ⁿ   Yew, Wing Wai ^o   Menzies, Dick ^p,q   Ahuja, S D ^a   Ashkin, D ^a   Avendano, M ^a   Banerjee, R ^a   Bauer, M ^a   Bayona, J N ^a   Becerra, M C ^a   Benedetti, A ^a   Burgos, M ^a   Centis, R ^a   Chan, E D ^a   Chiang, C Y ^a   Cox, H ^a   D'Ambrosio, L ^a   Deriemer, K ^a   Dung, N H ^a   Enarson, D ^a   Falzon, D ^a   Flanagan, K ^a   Flood, J ^a   Garcia Garcia, M L ^a   Gandhi, N ^a   Granich, R M ^a   Hollm Delgado, M G ^a   Holtz, T H ^a   Iseman, M D ^a   Jarlsberg, L G ^a   Keshavjee, S ^a   Kim, H R ^a   Koh, W J ^a   Lancaster, J ^a   Lange, C ^a   De Lange, W C M ^a   Li, J ^a   Migliori, G B ^a   Mishustin, S P ^a   Mitnick, C D ^a   O'Riordan, P ^a   Pai, M ^a   Palmero, D ^a   Park, S K ^a   Pasvol, G ^a   Pena, J ^a   Perez Guzman C ^a   Quelapio, M I D ^a   Riekstina, V ^a   Robert, J ^a   Royce, S ^a   Schaaf, H S ^a   Shah, L ^a   Shim, T S ^a   Shin, S S ^a   Shiraishi, Y ^a   Sotgiu, G ^a   Strand, M J ^a   Tabarsi, P ^a   Tupasi, T E ^a   Van Altena, R ^a   Van Der Werf, T S ^a   Vargas, M H ^a   Viiklepp, P ^a   Westenhouse, J ^a   Yim, J J ^a   more..

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Rio de Janeiro Tuberculosis Scientific League   (Brazil)

^c Interactive Research Development   (Pakistan)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^f Infectology Center of Latvia   (Latvia)

^g DEPARTMENT OF HEALTH   (Hong Kong)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l UNIVERSITY OF CAPE TOWN   (South Africa)

^m SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

ⁿ UNIVERSITY OF GRONINGEN   (Netherlands)

^o CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^p MCGILL UNIVERSITY   (Canada)

^q MCGILL UNIVERSITY   (Canada)

more..

Author keywords

Drug susceptibility test; Meta analysis; Multidrug resistant; Treatment outcomes; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT CODING; RELAPSE; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TREATMENT OUTCOME; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; ODDS RATIO; RISK FACTOR; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84918817893     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu619     Document Type: Article

References (56)

1. World Health Organization. Global tuberculosis report, 2013. Available at: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656-eng.pdf. Accessed 22 October 2013.
2. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-9.
3. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update. Available at: http://whqlibdoc.who.int/publications/2011/9789241501583-eng.pdf. Accessed 22 October 2013.
4. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs, 2008. Available at: http://whqlibdoc.who.int/hq/2008/WHO-HTM-TB-2008.392-eng.pdf. Accessed 22 October 2013.
5. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005;25:564-9.
6. Kim SJ, Espinal MA, Abe C, et al. Is second-line anti-tuberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis 2004;8:1157-8.
7. Kam KM, Sloutsky A, Yip CW, et al. Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 2010;14:282-8.
8. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLoS Med 2012;9:28.
9. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28.
10. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009;4:e6914.
11. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-61.
12. Akçakír Y. Correlates of treatment outcomes of multidrug-resistant tuberculosis (MDR-TB): a systematic review and meta-analysis. Montréal, Canada: McGill University, 2010.
13. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640-5.
14. Higgins JPT, Green G. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, 2008. Available at: http://www.cochrane-handbook.org. Accessed 30 April 2011.
15. Pinheiro JC, Bates DM. Approximations to the log-likelihood function in the nonlinear mixed-effects model. J Comput Graph Stat 1995;4:12-35.
16. Thompson SG, Turner RM, Warn DE. Multilevel models for metaanalysis, and their application to absolute risk differences. Stat Methods Med Res 2001;10:375-92.
17. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med 2000;19:3417-32.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539-58.
19. Schabenberger O. Introducing the GLIMMIX procedure for generalized linear mixed models, 2011. Available at: http://www2.sas.com/proceedings/sugi30/196-30.pdf. Accessed 2 July 2014.
20. Yarandi HN. Handling missing data with multiple imputation using PROC MI in SAS. Available at: http://analytics.ncsu.edu/sesug/2002/ST14.pdf. Accessed 2 July 2014.
21. Avendano M, Goldstein RS. Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients. Can Respir J 2000;7:383-9.
22. Burgos M, Gonzalez LC, Paz EA, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005;40:968-75.
23. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004;169:1103-9.
24. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrugresistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006;28:980-5.
25. Cox HS, Kalon S, Allamuratova S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One 2007;5:e13901.
26. De Riemer K, Garcia-Garcia L, Bobadilla-Del-Valle M, et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005;365:1239-45.
27. Escudero E, Pena JM, Alvarez-Sala R, Vazquez JJ, Ortega A. Multidrugresistant tuberculosis without HIV infection: success with individualised therapy. Int J Tuberc Lung Dis 2006;10:409-14.
28. Geerligs WA, Van Altena R, De Lange WCM, Van Soolingen D, Van Der Werf TS. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000;4:758-64.
29. Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005;293:2732-9.
30. Banerjee R, Allen J, Westenhouse J, et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin Infect Dis 2008;47:450-7.
31. Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, Weyer K. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis 2006;10:649-55.
32. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1075-82.
33. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrugresistant tuberculosis. Clin Infect Dis 2007;45:1290-5.
34. Kwon YS, Kim YH, Suh GY, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008;47:496-502.
35. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005;365:318-26.
36. Lockman S, Kruuner A, Binkin N, et al. Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis. Clin Infect Dis 2001;32:373-80.
37. Masjedi MR, Tabarsi P, Chitsaz E, et al. Outcome of treatment of MDRTB patients with standardised regimens, Iran, 2002-2006. Int J Tuberc Lung Dis 2008;12:750-5.
38. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007;30:623-6.
39. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-28.
40. Munsiff SS, Ahuja SD, Li J, Driver CR. Public-private collaboration for multidrug-resistant tuberculosis control in New York City. Int J Tuberc Lung Dis 2006;10:639-48.
41. Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik AE, Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 2001;120:343-8.
42. O'Riordan P, Schwab U, Logan S, et al. Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis: case control study. PLoS One 2008;3:0003173.
43. Palmero DJ, Ambroggi M, Brea A, et al. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 2004;8:778-84.
44. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004;8:361-8.
45. Perez-Guzman C, Vargas MH, Martinez-Rossier LA, Torres-Cruz A, Villarreal-Velarde H. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. Int J Tuberc Lung Dis 2002;6:1102-9.
46. Quy HT, Cobelens FG, Lan NT, Buu TN, Lambregts CS, Borgdorff MW. Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2006;10:45-51.
47. Schaaf HS, Shean K, Donald PR. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child 2003;88:1106-11.
48. Shin SS, Pasechnikov AD, Gelmanova IY, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006;10:402-8.
49. Shiraishi Y, Nakajima Y, Katsuragi N, Kurai M, Takahashi N. Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis. J Thorac Cardiovasc Surg 2004;128:523-8.
50. Tupasi TE, Gupta R, Quelapio MI, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006;3:e352.
51. Uffredi ML, Truffot-Pernot C, Dautzenberg B, Renard M, Jarlier V, Robert J. An intervention programme for the management of multidrugresistant tuberculosis in France. Int J Antimicrob Agents 2007;29:434-9.
52. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117:744-51.
53. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003;124:1476-81.
54. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60.
55. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrugresistant tuberculosis: long-termoutcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56:3271-6.
56. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007;4:e292.